Danaher Corp (DHR) Receives Buy Rating from Goldman Sachs
Goldman Sachs initiates coverage on Danaher Corp (DHR) with a Buy rating.
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 61,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Danaher Corp.
Last Updated: Dec 11, 2025, 11:03 PM · Source: Finnhub.io
Goldman Sachs initiates coverage on Danaher Corp (DHR) with a Buy rating.
Morgan Stanley has initiated coverage on Danaher Corp (DHR) with an Overweight rating.
RALES MITCHELL P sold 850,000 shares of Danaher Corp for $196.51M.
Danaher Corp (DHR) has announced a quarterly dividend of $0.32 per share, payable to shareholders in October.
Senator Sheldon Whitehouse sold shares of Danaher Corp (DHR) valued between $1K and $15K.
Insider Rales Mitchell P sold 964,373 shares of Danaher Corp (DHR) for $209.89 million.
Couchara Georgeann of Danaher Corp (DHR) sold 3,623 shares on November 9, 2025.
Danaher Corp (DHR) exceeded Q3 earnings expectations with strong results.